Digital health has entered a recalibration phase, with health systems and investors demanding measurable ROI from technology procurement and tightening governance around AI workflows, according to a new report from law firm Holland & Knight. The shift places chronic disease management and AI accountability at the center of deal activity and regulatory scrutiny, forcing healthcare operators to rethink how they evaluate, buy, and deploy digital tools.
AI workflow integration moves from pilot to accountability
Holland & Knight's report identifies AI workflow integration as one of two operational areas drawing the most transactional and regulatory attention. Health systems that spent the past two years running pilots now face pressure to formalize governance structures around those tools. That means defining who is accountable when an AI-assisted clinical or administrative decision goes wrong, and building documentation trails that satisfy internal compliance teams and external regulators.
For CIOs and CMIOs, the practical implication is clear: AI procurement can no longer sit entirely with a single department. Contracts for AI for Healthcare workflow tools increasingly require cross-functional sign-off from legal, compliance, and clinical operations, not just IT. The report's emphasis on litigation trends alongside transactional ones signals that post-deployment liability is already a live concern, not a future risk.
The governance question grows more acute for tools embedded directly in care delivery workflows. A coding assistant or prior authorization bot operating at scale creates a different compliance surface than a standalone analytics dashboard. Operators evaluating AI vendors should ask specifically how the vendor handles model updates, audit logging, and clinical override documentation.
Chronic disease management draws deal activity
The second major operational focus in the report is chronic disease management, a category spanning remote patient monitoring, condition-specific digital therapeutics, and population health platforms. This area attracts deal attention because it offers one of the clearest paths to demonstrating the ROI that recalibration-phase investors and health system CFOs now demand. Programs that reduce hospital readmissions or emergency department utilization for high-cost chronic conditions produce numbers that are relatively straightforward to audit.
For supply chain and vendor management teams, that concentration of deal activity means more vendor consolidation is likely. Smaller point solutions targeting single chronic conditions face acquisition or partnership pressure from larger platforms trying to offer integrated chronic care suites. Procurement leaders evaluating chronic care tools should factor platform longevity and integration roadmaps into their selection criteria, not just current functionality.
Regulatory exposure adds a new layer to vendor evaluation
Holland & Knight's report covers regulatory and litigation trends alongside the transactional picture, reflecting how intertwined compliance exposure and technology decisions have become. Digital health tools that touch billing, prior authorization, or clinical documentation carry fraud and abuse risk that did not exist when those processes were purely manual. As federal and state regulators increase scrutiny of AI-assisted billing and algorithmic decision support, health systems bear responsibility for the tools they deploy, not just the outcomes they produce.
Efficiency is the third theme the report emphasizes. The drive to reduce administrative burden through digital tools is real, but operators should approach efficiency claims with the same evidence standard now applied to clinical outcomes. A platform that promises to cut prior authorization time by a specific percentage should be able to show that figure from a comparable deployment, not just a modeled projection.
Why this matters for healthcare professionals
Healthcare procurement teams, CIOs, and clinical operations leaders should require outcome data rather than projections from digital health vendors. Ask for audited results from comparable health system deployments before advancing any contract, particularly for AI workflow and chronic care tools. Build cross-functional AI governance now: if your organization runs AI-assisted clinical or administrative workflows without a documented accountability framework, the regulatory environment makes that a near-term priority. Stress-test chronic care vendors on platform longevity given consolidation pressure in the category, and update RFP scorecards to weight measurable ROI evidence at least as heavily as feature sets and implementation timelines.
Your membership also unlocks:
